ADIL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ADIL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Adial Pharmaceuticals's Cost of Goods Sold for the three months ended in Dec. 2023 was $0.00 Mil. Its Revenue for the three months ended in Dec. 2023 was $0.00 Mil.
Adial Pharmaceuticals's COGS to Revenue for the three months ended in Dec. 2023 was 0.00.
Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Adial Pharmaceuticals's Gross Margin % for the three months ended in Dec. 2023 was N/A%.
The historical data trend for Adial Pharmaceuticals's COGS-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adial Pharmaceuticals Annual Data | |||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||||||
COGS-to-Revenue | Get a 7-Day Free Trial | - | - | - | - | - |
Adial Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
COGS-to-Revenue | Get a 7-Day Free Trial | - | - | - | - | - |
Adial Pharmaceuticals's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as
COGS to Revenue | = | Cost of Goods Sold | / | Revenue |
= | 0 | / | 0 | |
= |
Adial Pharmaceuticals's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as
COGS to Revenue | = | Cost of Goods Sold | / | Revenue |
= | 0 | / | 0 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adial Pharmaceuticals (NAS:ADIL) COGS-to-Revenue Explanation
Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.
Adial Pharmaceuticals's Gross Margin % for the three months ended in Dec. 2023 is calculated as:
Gross Margin % | = | 1 | - | COGS to Revenue |
= | 1 | - | Cost of Goods Sold / Revenue | |
= | 1 | - | 0 / 0 | |
= | N/A % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.
Thank you for viewing the detailed overview of Adial Pharmaceuticals's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Kevin Schuyler | director | 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901 |
Stilley William B. Iii | director, 10 percent owner, officer: Chief Executive Officer | 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901 |
Newman James W. Jr. | director | 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901 |
Cary J Claiborne | director | 3056 SENECA CHIEF TRAIL, ELLICOTT CITY MD 21042 |
Bankole A. Johnson | director, 10 percent owner | 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901 |
Jack W Reich | director | C/O COLLATERAL THERAPEUTICS, 11622 EL CAMINO REAL, SAN DIEGO CA 92130 |
Tony Goodman | director | 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901 |
J. Kermit Anderson | director | 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901 |
Joseph Truluck | officer: COO and CFO | 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901 |
Robertson H. Gilliland | director | 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901 |
En Fidecomiso De Mi Vida 11/23/2010 Trust | 10 percent owner | 11024 GAITHER FARM ROAD, ELLICOTT CITY MD 21042 |
From GuruFocus
By sperokesalga sperokesalga • 03-21-2023
By PurpleRose PurpleRose • 08-16-2022
By Marketwired • 09-05-2023
By Marketwired • 08-23-2023
By Marketwired • 08-28-2023
By PurpleRose PurpleRose • 07-14-2022
By Marketwired • 10-19-2023
By sperokesalga sperokesalga • 02-27-2023
By sperokesalga sperokesalga • 02-21-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.